Caenorhabditis elegans as a Screening Model for Probiotics with Properties against Metabolic Syndrome
International Journal of Molecular Sciences · 22.01.2024 · 25 (2) · 1321
DOI: 10.3390/ijms25021321 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.01.2024. Verfasst von Ignacio Goyache und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, Spain. Hauptthemen laut MEDLINE: Metabolic Syndrome, Diabetes Mellitus, Type 2, Probiotics. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gobierno de Navarra, Eatex Food Innovation Hub [PANACEA], MICINN.
Abstract (Originalsprache)
There is a growing need to develop new approaches to prevent and treat diseases related to metabolic syndromes, including obesity or type 2 diabetes, that focus on the different factors involved in the pathogenesis of these diseases. Due to the role of gut microbiota in the regulation of glucose and insulin homeostasis, probiotics with beneficial properties have emerged as an alternative therapeutic tool to ameliorate metabolic diseases-related disturbances, including fat excess or inflammation. In the last few years, different strains of bacteria, mainly lactic acid bacteria (LAB) and species from the genus Bifidobacterium, have emerged as potential probiotics due to their anti-obesogenic and/or anti-diabetic properties. However, in vivo studies are needed to demonstrate the mechanisms involved in these probiotic features. In this context, Caenorhabditis elegans has emerged as a very powerful simple in vivo model to study the physiological and molecular effects of probiotics with potential applications regarding the different pathologies of metabolic syndrome. This review aims to summarize the main studies describing anti-obesogenic, anti-diabetic, or anti-inflammatory properties of probiotics using C. elegans as an in vivo research model, as well as providing a description of the molecular mechanisms involved in these activities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, Spain.
- Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain.
- Genbioma Aplicaciones SL, Polígono Industrial Noain-Esquiroz, Calle S, Nave 4, 31191 Esquíroz, Spain.
- Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain.
- Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERObn), 28029 Madrid, Spain.
ORCID-Profile: Deyan Yavorov-Dayliev, Fermín I Milagro, Paula Aranaz
Förderung
- Gobierno de Navarra
- Eatex Food Innovation Hub [PANACEA]
- MICINN
Zitieren
APA
Goyache, I., Yavorov-Dayliev, D., Milagro, F. I., & Aranaz, P. (2024). Caenorhabditis elegans as a Screening Model for Probiotics with Properties against Metabolic Syndrome. International Journal of Molecular Sciences, 25(2), 1321. https://doi.org/10.3390/ijms25021321
Vancouver
Goyache I, Yavorov-Dayliev D, Milagro FI, Aranaz P. Caenorhabditis elegans as a Screening Model for Probiotics with Properties against Metabolic Syndrome. International Journal of Molecular Sciences. 2024;25(2):1321. doi:10.3390/ijms25021321
BibTeX
@article{Goyache2024,
author = {Goyache, Ignacio and Yavorov-Dayliev, Deyan and Milagro, Fermín I and Aranaz, Paula},
title = {Caenorhabditis elegans as a Screening Model for Probiotics with Properties against Metabolic Syndrome},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {2},
pages = {1321},
doi = {10.3390/ijms25021321}
}
EUVIMED